Anbio Biotechnology Class A Ordinary Shares (NNNN) Earnings History
Profitable5 years of earnings data (2021–2025) · Positive TTM net income
Loading earnings history...
Anbio Biotechnology Class A Ordinary Shares (NNNN) Earnings Overview
As of July 8, 2026, Anbio Biotechnology Class A Ordinary Shares (NNNN) reported trailing twelve-month net income of $5M, reflecting +185.7% year-over-year growth. The company earned $0.12 per diluted share over the past four quarters, with a net profit margin of 74.1%.
Looking at the long-term picture, NNNN's historical earnings data spans multiple years. The company achieved its highest annual net income of $10M in fiscal 2022.
Anbio Biotechnology Class A Ordinary Shares maintains industry-leading profitability with a gross margin of 87.2%, operating margin of 66.7%, and net margin of 74.1%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including CLOV (-$57M net income, -4.4% margin), ACHC (-$1.11B net income, -33.3% margin), QDEL (-$1.21B net income, -41.5% margin), NNNN has outperformed on profitability metrics. Compare NNNN vs CLOV →
NNNN Earnings vs Peers
Earnings metrics vs comparable public companies
NNNN Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6M | +169.9% | $6M | $0.16 | 74.1% | 66.7% |
| 2024 | $2M | +5.3% | $2M | $0.06 | 29.0% | 24.4% |
| 2023 | $2M | -77.5% | $2M | $0.01 | 33.6% | 29.2% |
| 2022 | $10M | +294.8% | $10M | $0.07 | 42.5% | 43.3% |
| 2021 | $3M | - | $2M | $0.03 | 57.3% | 55.5% |
Download Data
Export NNNN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NNNN — Frequently Asked Questions
Quick answers to the most common questions about buying NNNN stock.
What is NNNN earnings per share (EPS)?
NNNN trailing twelve-month (TTM) diluted EPS is $0.12, reflecting +185.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Anbio Biotechnology Class A Ordinary Shares's net income?
Anbio Biotechnology Class A Ordinary Shares (NNNN) trailing twelve-month net income is $5M as of 2025. Earnings grew +185.7% year-over-year. Anbio Biotechnology Class A Ordinary Shares has been profitable for 5 consecutive years.
Is NNNN profitable?
Yes, NNNN is profitable with a TTM net income of $5M and a net profit margin of +74.1%. Anbio Biotechnology Class A Ordinary Shares has generated profits for 5 consecutive years.
What is NNNN's earnings growth rate?
NNNN compound annual EPS growth rates (CAGR): 1-Year: +185.7%, 3-Year: +32.0%, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are NNNN's profit margins?
Anbio Biotechnology Class A Ordinary Shares net profit margin is +74.1%, operating margin is +66.7%, and gross margin is +87.2%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +27.0%.
Is NNNN growing earnings?
Yes, NNNN earnings are accelerating — EPS growth of +185.7% exceeds the 5-year CAGR of N/A. TTM net income reached $5M. Earnings momentum is strengthening.
What was NNNN's best earnings year?
Anbio Biotechnology Class A Ordinary Shares's highest annual net income on record is $10M, achieved in fiscal year 2022. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were NNNN's earnings last quarter?
NNNN's most recent reported quarter was Q4 2024. Net income was $-1M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.